Comprehensive panel boosts GIST diagnosis sensitivity
Answers from the Lab
Multiple genetic mutations are now known to cause gastrointestinal stromal tumors, or GIST. In this test specific episode of the "Answers From the Lab" podcast, Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' comprehensive MayoComplete GIST Panel, which covers these mutations for improved diagnosis and treatment.
"This expanded panel is more sensitive for the diagnosis of GIST. It covers not only the most commonly mutated genes but also the less commonly mutated genes and GIST mutations that pursue an aggressive disease course," Dr. Graham says.
The next generation sequencing assay can be used to confirm a diagnosis of GIST in patients who have unusual lesions in the GI tract. For patients already diagnosed with GIST, the assay can pinpoint genetic mutations that inform treatment and prognosis.
"This is a very complete GIST panel," Dr. Graham says. "It is part of a thoughtfully curated menu of tests that focus on all the genes surrounding a specific indication — such as GIST — and also standalone gene tests."
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
This assay requires at least 20% tumor nuclei
For specimen preparation guidance, see Tissue Requirement for Solid Tumor Next-Generation Sequencing. In this document, the sizes are given as 4mm x 4mm x 10 slides as preferred: approximate/equivalent to 144 mm(2) and the minimum as 3mm x 1mm x 10 slides: approximate/equivalent to 36mm(2).
Note: The total amount of required tumor nuclei can be obtained by scraping up to 10 slides from the same block
Additional Information: Unused unstained slides will not be returned
Note: Glass coverslips are preferred; plastic coverslips are acceptable but will result in longer turnaround times
Additional Information: Cytology slides will not be returned
Analytic time: 12 days
Days performed: Monday through Friday
Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately determine subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy.
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay measures concentrations of the small dense LDL subtype, to better guide clinical care.
Identifying a precise genetic cause of hearing loss impacts clinical management. Nicole Boczek, Ph.D., and Melanie Meyer, M.S., CGC, explain how Mayo Clinic Laboratories' updated panel yields comprehensive results for optimal patient care.